CN109170305A - 改善宠物肝功能的处方膏及其制备方法 - Google Patents
改善宠物肝功能的处方膏及其制备方法 Download PDFInfo
- Publication number
- CN109170305A CN109170305A CN201810878576.6A CN201810878576A CN109170305A CN 109170305 A CN109170305 A CN 109170305A CN 201810878576 A CN201810878576 A CN 201810878576A CN 109170305 A CN109170305 A CN 109170305A
- Authority
- CN
- China
- Prior art keywords
- vitamin
- liver function
- cream
- prescription
- extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000006071 cream Substances 0.000 title claims abstract description 37
- 230000003908 liver function Effects 0.000 title claims abstract description 29
- 238000002360 preparation method Methods 0.000 title claims abstract description 16
- 239000000284 extract Substances 0.000 claims abstract description 32
- 235000008422 Schisandra chinensis Nutrition 0.000 claims abstract description 18
- 241000756943 Codonopsis Species 0.000 claims abstract description 17
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 claims abstract description 17
- 229960000367 inositol Drugs 0.000 claims abstract description 17
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 claims abstract description 17
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 claims abstract description 17
- 238000003756 stirring Methods 0.000 claims abstract description 17
- 241001632410 Eleutherococcus senticosus Species 0.000 claims abstract description 16
- 239000000843 powder Substances 0.000 claims abstract description 16
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 claims abstract description 15
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 15
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 claims abstract description 15
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims abstract description 15
- 229940107666 astragalus root Drugs 0.000 claims abstract description 15
- 239000001768 carboxy methyl cellulose Substances 0.000 claims abstract description 15
- 235000021323 fish oil Nutrition 0.000 claims abstract description 15
- 229940010454 licorice Drugs 0.000 claims abstract description 15
- 239000002994 raw material Substances 0.000 claims abstract description 15
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims abstract description 15
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims abstract description 15
- 235000001287 Guettarda speciosa Nutrition 0.000 claims abstract description 14
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 claims abstract description 14
- 241000287828 Gallus gallus Species 0.000 claims abstract description 13
- 238000000605 extraction Methods 0.000 claims abstract description 13
- 239000004615 ingredient Substances 0.000 claims abstract description 12
- 235000012054 meals Nutrition 0.000 claims abstract description 12
- 229940088594 vitamin Drugs 0.000 claims abstract description 11
- 229930003231 vitamin Natural products 0.000 claims abstract description 11
- 235000013343 vitamin Nutrition 0.000 claims abstract description 11
- 239000011782 vitamin Substances 0.000 claims abstract description 11
- 150000003722 vitamin derivatives Chemical class 0.000 claims abstract description 11
- WHMDKBIGKVEYHS-IYEMJOQQSA-L Zinc gluconate Chemical compound [Zn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O WHMDKBIGKVEYHS-IYEMJOQQSA-L 0.000 claims abstract description 10
- 229960000306 zinc gluconate Drugs 0.000 claims abstract description 10
- 235000011478 zinc gluconate Nutrition 0.000 claims abstract description 10
- 239000011670 zinc gluconate Substances 0.000 claims abstract description 10
- 244000061520 Angelica archangelica Species 0.000 claims abstract 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 16
- 241000736075 Schisandra Species 0.000 claims description 15
- 241000202807 Glycyrrhiza Species 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- FAPWYRCQGJNNSJ-UHFFFAOYSA-L Calcium DL-pantothenate Chemical compound [Ca+2].OCC(C)(C)C(O)C(=O)NCCC([O-])=O.OCC(C)(C)C(O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UHFFFAOYSA-L 0.000 claims description 9
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 9
- 229960003512 nicotinic acid Drugs 0.000 claims description 9
- 235000001968 nicotinic acid Nutrition 0.000 claims description 9
- 239000011664 nicotinic acid Substances 0.000 claims description 9
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 8
- 229930003427 Vitamin E Natural products 0.000 claims description 8
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 claims description 8
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 8
- 230000007062 hydrolysis Effects 0.000 claims description 8
- 238000006460 hydrolysis reaction Methods 0.000 claims description 8
- 239000011715 vitamin B12 Substances 0.000 claims description 8
- 239000011716 vitamin B2 Substances 0.000 claims description 8
- 235000019165 vitamin E Nutrition 0.000 claims description 8
- 229940046009 vitamin E Drugs 0.000 claims description 8
- 239000011709 vitamin E Substances 0.000 claims description 8
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 claims description 7
- 239000011691 vitamin B1 Substances 0.000 claims description 7
- 238000009835 boiling Methods 0.000 claims description 5
- 238000000265 homogenisation Methods 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 3
- 244000170916 Paeonia officinalis Species 0.000 claims description 2
- 235000006484 Paeonia officinalis Nutrition 0.000 claims description 2
- 239000009636 Huang Qi Substances 0.000 claims 1
- 208000019423 liver disease Diseases 0.000 abstract description 7
- 238000010438 heat treatment Methods 0.000 abstract description 4
- 240000006079 Schisandra chinensis Species 0.000 abstract description 3
- 230000006870 function Effects 0.000 abstract description 3
- 230000006872 improvement Effects 0.000 abstract description 3
- 240000004670 Glycyrrhiza echinata Species 0.000 abstract 1
- 210000004185 liver Anatomy 0.000 description 19
- 238000012360 testing method Methods 0.000 description 12
- 241000125175 Angelica Species 0.000 description 9
- 241000700159 Rattus Species 0.000 description 9
- 210000005229 liver cell Anatomy 0.000 description 8
- 239000013642 negative control Substances 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 239000006210 lotion Substances 0.000 description 6
- 206010028851 Necrosis Diseases 0.000 description 5
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 5
- 238000009098 adjuvant therapy Methods 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 230000035611 feeding Effects 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 230000017074 necrotic cell death Effects 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 239000011701 zinc Substances 0.000 description 5
- 229910052725 zinc Inorganic materials 0.000 description 5
- 108010062580 Concanavalin A Proteins 0.000 description 4
- 241000282326 Felis catus Species 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 235000001727 glucose Nutrition 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 230000004580 weight loss Effects 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 208000022531 anorexia Diseases 0.000 description 3
- 206010061428 decreased appetite Diseases 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- -1 Alba polysaccharide Chemical class 0.000 description 2
- 208000004930 Fatty Liver Diseases 0.000 description 2
- 206010019708 Hepatic steatosis Diseases 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000009188 angelicae sinensis extract Substances 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 208000010706 fatty liver disease Diseases 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 231100000753 hepatic injury Toxicity 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 230000003859 lipid peroxidation Effects 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- NEGYEDYHPHMHGK-UHFFFAOYSA-N para-methoxyamphetamine Chemical compound COC1=CC=C(CC(C)N)C=C1 NEGYEDYHPHMHGK-UHFFFAOYSA-N 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- YEFOAORQXAOVJQ-RZFZLAGVSA-N schisandrol a Chemical compound C1[C@H](C)[C@@](C)(O)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC YEFOAORQXAOVJQ-RZFZLAGVSA-N 0.000 description 2
- 231100000240 steatosis hepatitis Toxicity 0.000 description 2
- 102000003390 tumor necrosis factor Human genes 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- 230000004584 weight gain Effects 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- 208000016261 weight loss Diseases 0.000 description 2
- KSDSYIXRWHRPMN-UHFFFAOYSA-N 4'-O-beta-D-Galactopyranoside-6''-p-Coumaroylprunin-4',5,7-Trihydroxyflavanone Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(C2OC3=CC(O)=CC(O)=C3C(=O)C2)C=C1 KSDSYIXRWHRPMN-UHFFFAOYSA-N 0.000 description 1
- BKGUPIVDQHHVMV-LSHKVNPSSA-N 64938-51-8 Chemical compound COC1=C2C=3C(OC)=C(OC)C(OC)=CC=3[C@H](OC(=O)C(\C)=C\C)[C@@](C)(O)[C@@H](C)CC2=CC2=C1OCO2 BKGUPIVDQHHVMV-LSHKVNPSSA-N 0.000 description 1
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 1
- 108010082126 Alanine transaminase Proteins 0.000 description 1
- 241000208340 Araliaceae Species 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 102100030703 Interleukin-22 Human genes 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 1
- DEMKZLAVQYISIA-ONJCETCRSA-N Liquiritin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)c1ccc([C@@H]2Oc3c(C(=O)C2)ccc(O)c3)cc1 DEMKZLAVQYISIA-ONJCETCRSA-N 0.000 description 1
- DEMKZLAVQYISIA-UHFFFAOYSA-N Liquirtin Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(C2OC3=CC(O)=CC=C3C(=O)C2)C=C1 DEMKZLAVQYISIA-UHFFFAOYSA-N 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 102000049939 Smad3 Human genes 0.000 description 1
- 108700031297 Smad3 Proteins 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 206010048259 Zinc deficiency Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 231100000354 acute hepatitis Toxicity 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000002547 anomalous effect Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 210000000702 aorta abdominal Anatomy 0.000 description 1
- QMNWISYXSJWHRY-YLNUDOOFSA-N astragaloside IV Chemical compound O1[C@H](C(C)(O)C)CC[C@]1(C)[C@@H]1[C@@]2(C)CC[C@]34C[C@]4(CC[C@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)CO4)O)C4(C)C)[C@H]4[C@@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)C[C@H]3[C@]2(C)C[C@@H]1O QMNWISYXSJWHRY-YLNUDOOFSA-N 0.000 description 1
- QMNWISYXSJWHRY-BCBPIKMJSA-N astragaloside IV Natural products CC(C)(O)[C@@H]1CC[C@@](C)(O1)[C@H]2[C@@H](O)C[C@@]3(C)[C@@H]4C[C@H](O[C@@H]5O[C@H](CO)[C@H](O)[C@@H](O)[C@H]5O)[C@H]6C(C)(C)[C@H](CC[C@@]67C[C@@]47CC[C@]23C)O[C@@H]8OC[C@@H](O)[C@H](O)[C@H]8O QMNWISYXSJWHRY-BCBPIKMJSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 208000010717 cat disease Diseases 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- PFKIBRPYVNVMRU-UHFFFAOYSA-N cyclosieversioside F Natural products CC(C)(O)C1COC(C)(C1)C2C(O)CC3(C)C4CC(OC5OC(CO)C(O)C(O)C5O)C6C(C)(C)C(CCC67CC47CCC23C)OC8OCC(O)C(O)C8O PFKIBRPYVNVMRU-UHFFFAOYSA-N 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- JEJFTTRHGBKKEI-OKILXGFUSA-N deoxyschizandrin Chemical compound C1[C@H](C)[C@H](C)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC JEJFTTRHGBKKEI-OKILXGFUSA-N 0.000 description 1
- JEJFTTRHGBKKEI-UHFFFAOYSA-N deoxyschizandrin Natural products C1C(C)C(C)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC JEJFTTRHGBKKEI-UHFFFAOYSA-N 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 235000019621 digestibility Nutrition 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 239000001685 glycyrrhizic acid Substances 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 230000002443 hepatoprotective effect Effects 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 230000003118 histopathologic effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 229940088592 immunologic factor Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 108010074109 interleukin-22 Proteins 0.000 description 1
- 229930013686 lignan Natural products 0.000 description 1
- 235000009408 lignans Nutrition 0.000 description 1
- 150000005692 lignans Chemical class 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- DEMKZLAVQYISIA-ZRWXNEIDSA-N liquiritin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C([C@H]2OC3=CC(O)=CC=C3C(=O)C2)C=C1 DEMKZLAVQYISIA-ZRWXNEIDSA-N 0.000 description 1
- 231100000832 liver cell necrosis Toxicity 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 201000003102 mental depression Diseases 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 239000003726 plant lectin Substances 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 210000003240 portal vein Anatomy 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- FYSHYFPJBONYCQ-UHFFFAOYSA-N schisanhenol Natural products C1C(C)C(C)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2O FYSHYFPJBONYCQ-UHFFFAOYSA-N 0.000 description 1
- BKGUPIVDQHHVMV-UHFFFAOYSA-N schisantherin C Natural products COC1=C2C=3C(OC)=C(OC)C(OC)=CC=3C(OC(=O)C(C)=CC)C(C)(O)C(C)CC2=CC2=C1OCO2 BKGUPIVDQHHVMV-UHFFFAOYSA-N 0.000 description 1
- 229930193195 schizandrin Natural products 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-N sodium;5-ethyl-5-pentan-2-yl-1,3-diazinane-2,4,6-trione Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)NC1=O QGMRQYFBGABWDR-UHFFFAOYSA-N 0.000 description 1
- GSZUGBAEBARHAW-UHFFFAOYSA-N sophoraflavone B Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(C=2OC3=CC(O)=CC=C3C(=O)C=2)C=C1 GSZUGBAEBARHAW-UHFFFAOYSA-N 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- YEFOAORQXAOVJQ-UHFFFAOYSA-N wuweizischun A Natural products C1C(C)C(C)(O)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC YEFOAORQXAOVJQ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
- A23K50/48—Moist feed
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/30—Animal feeding-stuffs from material of plant origin, e.g. roots, seeds or hay; from material of fungal origin, e.g. mushrooms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/105—Aliphatic or alicyclic compounds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/142—Amino acids; Derivatives thereof
- A23K20/147—Polymeric derivatives, e.g. peptides or proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/174—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/20—Inorganic substances, e.g. oligoelements
- A23K20/24—Compounds of alkaline earth metals, e.g. magnesium
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/20—Inorganic substances, e.g. oligoelements
- A23K20/30—Oligoelements
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/315—Zinc compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A61K31/51—Thiamines, e.g. vitamin B1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
- A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/254—Acanthopanax or Eleutherococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/344—Codonopsis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/57—Magnoliaceae (Magnolia family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/79—Schisandraceae (Schisandra family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/41—Porphyrin- or corrin-ring-containing peptides
- A61K38/42—Haemoglobins; Myoglobins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Polymers & Plastics (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Food Science & Technology (AREA)
- Zoology (AREA)
- Animal Husbandry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Physiology (AREA)
- Birds (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本发明公开了一种改善宠物肝功能的处方膏,包括以下原料组分:五味子提取物、甘草提取物、当归提取物、黄芪提取物、刺五加提取物、党参提取物、白芍提取物、肌醇、血红素蛋白粉、鱼油、牛水解膏、鸡肉粉、羧甲基纤维素钠、葡萄糖酸锌。本发明的改善宠物肝功能的处方膏具有辅助治疗宠物肝脏疾病和改善宠物肝功能的作用。本发明还公开了改善宠物肝功能的处方膏的制备方法,通过将大部分原料先进行加热搅拌均匀,再将维生素加入进行加热,使得后集中成分不易加热太久被破坏掉,所述制备方法简单,便于操作。
Description
技术领域
本发明涉及宠物用营养品技术领域,特别涉及改善宠物肝功能的处方膏及其制备方法。
背景技术
肝脏是犬猫机体最重要的器官之一,生理功能广泛,主疏泻、主藏血、主筋,开窍于目,血液、筋骨、脾胃、精神、双目等无一不与肝脏的生理功能密切相关。犬猫的肝脏疾病非常常见,对犬猫机体的损伤和危害不可估量。动物主人和宠物医生都应该重视犬猫的肝脏疾病,及早发现,及时治疗。目前宠物市场上,还没有利用天然草本植物辅助治疗宠物肝脏疾病和改善宠物肝功能的处方膏体。
发明内容
根据本发明的一个方面,提供了一种改善宠物肝功能的处方膏,包括以下原料组分:五味子提取物、甘草提取物、当归提取物、黄芪提取物、刺五加提取物、党参提取物、白芍提取物、肌醇、血红素蛋白粉、鱼油、牛水解膏、鸡肉粉、羧甲基纤维素钠、葡萄糖酸锌。
其中,改善宠物肝功能的处方膏还包括维生素。
其中,维生素包括维生素B1、维生素B2、维生素B12、DL-泛酸钙、烟酸和维生素E中的一种或多种。
进一步的,改善宠物肝功能的处方膏包括下列质量百分数含量的原料:五味子提取物:0.05%-0.2%、甘草提取物:0.2%-1%、当归提取物:0.05%-0.3%、黄芪提取物:0.5%-2.0%、刺五加提取物:0.5%-2.5%、党参提取物:0.1%-1%、白芍提取物:0.1%-1%、肌醇:1%-4%、血红素蛋白粉:1%-6%、鱼油:8%-15%、牛水解膏:5%-15%、鸡肉粉:2%-10%、羧甲基纤维素钠:1%-1.5%、葡萄糖酸锌:1.2%、维生素B1:0.01%、维生素B2:0.01%、维生素B12:0.01%、DL-泛酸钙:0.05%、烟酸:0.1%、维生素E:0.25%,余量由水补足。
更进一步的,优选原料配方及其质量百分数含量为:五味子提取物:0.12%、甘草提取物:0.6%、当归提取物:0.15%、黄芪提取物:1%、刺五加提取物:0.9%、党参提取物:0.5%、白芍提取物:0.5%、肌醇:2%、血红素蛋白粉:4%、鱼油:10%、牛水解膏:8%、鸡肉粉:5%、羧甲基纤维素钠:1.13%。
其中,各原料的有益效果如下:
五味子提取物:五味子提取物中均含有五味子醇甲、五味子酯甲、五味子甲素和五味子乙素等木脂素类成分,这些成分是五味子保肝作用的主要物质基础,具有改善肝功能、减轻肝细胞脂质过氧化损伤,从而防止肝纤维化的作用。
甘草提取物:现代药学研究表明,干草中甘草酸、甘草苷等活性成分具有抗炎、解毒、抗氧化等多种药理活性,而甘草多糖对急性肝损伤具有保护作用;该保护作用与其抗氧化,抑制NOS、NO生成,减少自由基的产生等有关。
当归提取物:当归提取物中的当归多糖可提高肝组织细胞的抗氧化能力,抑制细胞凋亡,促进组织细胞损伤修复,对肝损伤具有一定的保护作用。
黄芪提取物:黄芪甲苷可以明显抑制肝脏组织纤维化和纤维组织增生,缓解炎症细胞浸润,并能显著降低肝脏组织中的TGF-β和Smad-3蛋白表达。
刺五加提取物:近年来研究表明,刺五加和人参具有相似的药理作用和临床疗效,可增加机体的免疫功能,提高机体对各种有害刺激非特异性的抵抗力和抗癌作用,刺五加对肝脏有较好的保护作用。
党参提取物:党参提取物可增强机体的抗氧化能力,缓解脂质过氧化对机体造成的损伤,减轻肝租住的超微结构异常变化,从而延缓衰老的进程。
白芍提取物:白芍总苷对肝脏有保护的作用,其作用机理是:提高抗氧化能力,降低异常免疫因子水平;白芍多糖具有一定的降酶保肝作用,其作用是通过增强体内自由基清除能力、保护细胞膜及抑制脂质过氧化反应等方面来实现的。
肌醇:肌醇能减轻肝脏氧化损伤,促进脂类代谢,降低脂肪肝的产生,提高机体免疫力,还能够促进宠物生长。
血红素蛋白粉:富含丰富的蛋白质,高消化率,含有有机铁,吸收率高,补充铁元素,预防和辅助治疗宠物贫血,保护肝脏。
葡萄糖酸锌:锌作为动物体内不可缺少的微量元素物质,是一种重要的抗氧化物质,可增加食欲,拮抗肝脏铜中毒。机体缺锌,可引起机体免疫功能减退。
维生素B1:缺乏会导致厌食、体重下降,呕吐等。
维生素B2:缺乏导致食欲减退,体重减轻、脂肪肝。
维生素B12:缺乏会出现体重下降、腹泻、呕吐、胆管肝炎等。
DL-泛酸钙:机体缺乏DL-泛酸钙会造成肝功能障碍。
烟酸:缺乏会导致厌食、体重下降,肝脏缺乏烟酸会导致脱水、衰弱和死亡。
维生素E:抗氧化作用,缺乏表现为精神抑郁,厌食,脂肪炎和肝脏门静脉单核细胞浸润。
上述原料通过特定比例配合加入改善宠物肝功能的处方膏中,具有辅助治疗宠物肝脏疾病和改善宠物肝功能的作用。
本发明的另一方面提供了改善宠物肝功能的处方膏的制备方法,所述方法包括:
(1)五味子提取物、甘草提取物、当归提取物、黄芪提取物、刺五加提取物、党参提取物、白芍提取物、肌醇、血红素蛋白粉、鱼油、牛水解膏、鸡肉粉、羧甲基纤维素钠和葡萄糖酸锌按配方比例称量投入配料罐内,按配方比例加入水均质搅拌成浆;
(2)开启配料罐的进汽开关,将步骤(1)所得产物边搅拌边加热到70-80℃时;
(3)将步骤(2)所得产物搅拌煮沸后依次加入按配方比例称量所得的维生素至配料罐中,继续煮沸20-30分钟。
其中,配料罐为蒸汽加热配料罐。
其中,配料罐的蒸汽压控制为0.2-0.4MPa。
其中,所述配料罐的蒸汽压优选为0.3MPa。
上述制备方法将大部分原料先进行加热搅拌均匀,再将维生素加入进行加热,使得后集中成分不易加热太久被破坏掉,所述制备方法简单,便于操作。
具体实施方式
下面结合实施例对发明作进一步详细的说明。
实施例1
原料总量为100公斤。其中,五味子提取物:0.05公斤、甘草提取物:0.2公斤、当归提取物:0.05公斤、黄芪提取物:0.5公斤、刺五加提取物:0.5公斤、党参提取物:0.1公斤、白芍提取物:0.1公斤、肌醇:1公斤、血红素蛋白粉:1公斤、鱼油:15公斤、牛水解膏:15公斤、鸡肉粉:2公斤、羧甲基纤维素钠:1kg、葡萄糖酸锌:1.2公斤、维生素B1:0.01公斤、维生素B2:0.01公斤、维生素B12:0.01公斤、DL-泛酸钙:0.05公斤、烟酸:0.1公斤、维生素E:0.25公斤、水:61.87公斤。
制备方法:
(1)五味子提取物、甘草提取物、当归提取物、黄芪提取物、刺五加提取物、党参提取物、白芍提取物、肌醇、血红素蛋白粉、鱼油、牛水解膏、鸡肉粉、羧甲基纤维素钠和葡萄糖酸锌按配方比例称量投入配料罐内,按配方比例加入水均质搅拌成浆;
(2)开启配料罐的进汽开关,将步骤(1)所得产物边搅拌边加热到70℃时;
(3)将步骤(2)所得产物搅拌煮沸后依次加入按配方比例称量所得的维生素至配料罐中,继续煮沸20分钟。
其中,配料罐为蒸汽加热配料罐,配料罐的蒸汽压为0.2MPa。
实施例2
原料总量为100公斤。其中,五味子提取物:0.12公斤、甘草提取物:0.6公斤、当归提取物:0.15公斤、黄芪提取物:1公斤、刺五加提取物:0.9公斤、党参提取物:0.5公斤、白芍提取物:0.5公斤、肌醇:2公斤、血红素蛋白粉:4公斤、鱼油:10公斤、牛水解膏:8公斤、鸡肉粉:5公斤、羧甲基纤维素钠:1.13kg、葡萄糖酸锌:1.2公斤、维生素B1:0.01公斤、维生素B2:0.01公斤、维生素B12:0.01公斤、DL-泛酸钙:0.05公斤、烟酸:0.1公斤、维生素E:0.25公斤、水:64.47公斤。
制备方法:
(1)五味子提取物、甘草提取物、当归提取物、黄芪提取物、刺五加提取物、党参提取物、白芍提取物、肌醇、血红素蛋白粉、鱼油、牛水解膏、鸡肉粉、羧甲基纤维素钠和葡萄糖酸锌按配方比例称量投入配料罐内,按配方比例加入水均质搅拌成浆;
(2)开启配料罐的进汽开关,将步骤(1)所得产物边搅拌边加热到75℃时;
(3)将步骤(2)所得产物搅拌煮沸后依次加入按配方比例称量所得的维生素至配料罐中,继续煮沸25分钟。
其中,配料罐为蒸汽加热配料罐,配料罐的蒸汽压为0.3MPa。
实施例3
原料总量为100公斤。其中,五味子提取物:0.2公斤、甘草提取物:1公斤、当归提取物:0.05公斤、黄芪提取物:2公斤、刺五加提取物:2.5公斤、党参提取物:1公斤、白芍提取物:1公斤、肌醇:4公斤、血红素蛋白粉:6公斤、鱼油:8公斤、牛水解膏:5公斤、鸡肉粉:10公斤、羧甲基纤维素钠:1.5kg、葡萄糖酸锌:1.2公斤、维生素B1:0.01公斤、维生素B2:0.01公斤、维生素B12:0.01公斤、DL-泛酸钙:0.05公斤、烟酸:0.1公斤、维生素E:0.25公斤、水:56.12公斤。
制备方法:
(1)五味子提取物、甘草提取物、当归提取物、黄芪提取物、刺五加提取物、党参提取物、白芍提取物、肌醇、血红素蛋白粉、鱼油、牛水解膏、鸡肉粉、羧甲基纤维素钠和葡萄糖酸锌按配方比例称量投入配料罐内,按配方比例加入水均质搅拌成浆;
(2)开启配料罐的进汽开关,将步骤(1)所得产物边搅拌边加热到80℃时;
(3)将步骤(2)所得产物搅拌煮沸后依次加入按配方比例称量所得的维生素至配料罐中,继续煮沸30分钟。
其中,配料罐为蒸汽加热配料罐,配料罐的蒸汽压为0.4MPa。
改善宠物肝功能的处方膏大鼠功效试验
改善宠物肝功能的处方膏用于犬猫急、慢性肝炎,缓解所致肋痛、黄疸等症状,是辅助治疗肝脏疾病与改善肝功能的宠物营养保健食品。本试验根据自主设计评估指标,选取刀豆蛋白A急性肝损伤模型大鼠作为试验研究对象,对照比较分析三组应用例的肝脏相关指标。
1原理:刀豆蛋白A(concanavalin A,ConA)是一种在人体内对肝细胞有特异性毒性作用的植物凝集素,它能在体外激活T细胞的丝裂原,进入循环后首先活化T淋巴细胞,继而激活肿瘤坏死因子(TNF)和白介素2等细胞因子,引发炎症反应,可诱导淋巴细胞、巨噬细胞的细胞毒作用,通过肝细胞凋亡等多种途径损伤肝细胞。
2试验动物:选取SPF级成年雄性SD大鼠50只,大鼠体重180-220克,由广东省医学实验动物中心提供。试验前对动物饲养观察7-10天,以适应饲养环境;试验环境为温度20-26℃,相对湿度50-70%。
3供试品:分别按照本发明的实施例1、2、3中的原料配方及其制备方法进行制作,按照推荐剂量折算成大鼠剂量,再加入纯净水进行配制形成三种食用液体膏体备用。
4试验分组:将50只大鼠随机分成五组,每组10只,分别是阴性对照组、模型对照组及应用例1、2、3三组。其中应用例1组饲喂按本发明实施例1的方案制作的食用液体膏体;应用例2组饲喂按本发明实施例2的方案制作的食用液体膏体;应用例3组饲喂按本发明实施例3的方案制作的食用液体膏体,自由采食与饮水。
5试验方法:应用例组每日经口灌胃给予供试品,阴性对照组和模型对照组给予纯净水,连续给予30天。模型对照组及各应用例组于实验结束时一次尾静脉给予剂量为20mg/kg的刀豆蛋白A,禁食8h后经腹腔注射60mg/kg BW的戊巴比妥钠溶液麻醉,腹主动脉采血,并取肝组织,进行各项指标的检测及病理组织学检查。
6评价指标
6.1体重:每周称一次体重,计算各组大鼠试验前后体重的增重。
6.2生化检测:实验结束后采血,使用全自动生化分析仪检测血液中谷丙转氨酶(ALT)、血清中谷草转氨酶(AST)、血清中乳酸脱氢酶(LDH)含量。
6.3肝脏病理组织学变化:剖检后取肝脏进行常规病理制片,镜检从肝脏的一端视野开始记录细胞的病理变化,用5倍物镜连续观察整张组织切片。其评分标准如下:肝细胞坏死
7数据处理:试验数据用SPSS20.0统计软件先进行方差齐性检验,再进行方差分析。
8结果判定:在模型成立的前提下,ALT、AST和LDH中任两项血液生化指标显著性降低(P<0.05或0.01)和病理结果肝细胞坏死程度显著性降低(P<0.05或0.01),可判定供试样品对肝脏损伤有辅助治疗与改善功能。
9结果
9.1体重:试验结束后,模型对照组及应用例1、2、3三组与阴性对照组比较,均无显著性差异(方差齐,P>0.05),详见表1。提示应用例1、2、3三组连续灌喂上述对应的食用液体膏体30天对大鼠增重无不良影响。
9.2生化检测:由表2所示,模型对照组与阴性对照组比较,血清ALT、AST和LDH含量显著性升高(P<0.01),表示模型成立。在模型成立的前提下,应用例1、2、3组血清ALT、AST含量与模型对照组比较显著性降低(P<0.05),应用例1、2、3组血清LDH含量与模型对照组比较,虽然无显著性差异(P>0.05),但有较为明显降低的趋势。
表1试验各组大鼠增重情况(n=10,)
表2试验各组ALT、AST、LDH指标情况(n=10,)
注:“a”表示模型对照组与阴性对照组比较P<0.05或0.01;“b”表示应用例组与模型对照组比较P<0.05或0.01。
9.3肝脏病理组织学变化:由表3所示,模型对照组与阴性对照组比较,肝细胞坏死程度显著性加重(P<0.01),表示模型成立。在模型成立的前提下,应用例1、2、3组肝细胞坏死程度与模型对照组比较显著性降低(P<0.01)。
表3试验各组肝细胞坏死程度情况
项目\组别 | 阴性对照组 | 模型对照组 | 应用例1组 | 应用例2组 | 应用例3组 |
坏死程度 | 0.9±0.6 | 3.4±1.0<sup>a</sup> | 2.6±0.8<sup>b</sup> | 2.1±0.9<sup>b</sup> | 2.3±1.0<sup>b</sup> |
注:“a”表示模型对照组与阴性对照组比较P<0.05或0.01;“b”表示应用例组与模型对照组比较P<0.05或0.01。
10结论:综上所述,在模型成立的前提下,各应用例组与模型对照组比较,ALT、AST两项血液生化指标显著性降低(P<0.05或0.01)和病理结果肝细胞坏死程度显著性降低(P<0.05或0.01),可判定应用例1、2、3组均对肝脏损伤有辅助治疗与改善功能;且从应用例1、2、3三组整体数据表现来看,应用例2组辅助治疗宠物肝脏疾病和改善宠物肝功能的效果最佳,即本发明实施例2为治疗宠物肝脏疾病和改善宠物肝功能的最佳实施方式。
以上所述的仅是本发明的一些实施方式。对于本领域的普通技术人员来说,在不脱离本发明创造构思的前提下,还可以做出若干变形和改进,这些都属于本发明的保护范围。
Claims (9)
1.改善宠物肝功能的处方膏,其特征在于:包括以下原料组分:五味子提取物、甘草提取物、当归提取物、黄芪提取物、刺五加提取物、党参提取物、白芍提取物、肌醇、血红素蛋白粉、鱼油、牛水解膏、鸡肉粉、羧甲基纤维素钠、葡萄糖酸锌。
2.根据权利要求1所述的改善宠物肝功能的处方膏,其特征在于:还包括维生素。
3.根据权利要求2所述的改善宠物肝功能的处方膏,其特征在于:所述维生素包括维生素B1、维生素B2、维生素B12、DL-泛酸钙、烟酸和维生素E中的一种或多种。
4.根据权利要求3所述的改善宠物肝功能的处方膏,其特征在于:包括下列质量百分数含量的原料:五味子提取物:0.05%-0.2%、甘草提取物:0.2%-1%、当归提取物:0.05%-0.3%、黄芪提取物:0.5%-2.0%、刺五加提取物:0.5%-2.5%、党参提取物:0.1%-1%、白芍提取物:0.1%-1%、肌醇:1%-4%、血红素蛋白粉:1%-6%、鱼油:8%-15%、牛水解膏:5%-15%、鸡肉粉:2%-10%、羧甲基纤维素钠:1%-1.5%、葡萄糖酸锌:1.2%、维生素B1:0.01%、维生素B2:0.01%、维生素B12:0.01%、DL-泛酸钙:0.05%、烟酸:0.1%、维生素E:0.25%,余量由水补足。
5.根据权利要求4所述的改善宠物肝功能的处方膏,其特征在于:优选原料配方及其质量百分数含量为:五味子提取物:0.12%、甘草提取物:0.6%、当归提取物:0.15%、黄芪提取物:1%、刺五加提取物:0.9%、党参提取物:0.5%、白芍提取物:0.5%、肌醇:2%、血红素蛋白粉:4%、鱼油:10%、牛水解膏:8%、鸡肉粉:5%、羧甲基纤维素钠:1.13%。
6.一种如权利要求1-5任一项所述的改善宠物肝功能的处方膏的制备方法,其特征在于:所述方法包括:
(1)五味子提取物、甘草提取物、当归提取物、黄芪提取物、刺五加提取物、党参提取物、白芍提取物、肌醇、血红素蛋白粉、鱼油、牛水解膏、鸡肉粉、羧甲基纤维素钠和葡萄糖酸锌按配方比例称量投入配料罐内,按配方比例加入水均质搅拌成浆;
(2)开启配料罐的进汽开关,将步骤(1)所得产物边搅拌边加热到70-80℃时;
(3)将步骤(2)所得产物搅拌煮沸后依次加入按配方比例称量所得的维生素至配料罐中,继续煮沸20-30分钟。
7.根据权利要求6所述的改善宠物肝功能的处方膏的制备方法,其特征在于:所述配料罐为蒸汽加热配料罐。
8.根据权利要求7所述的改善宠物肝功能的处方膏的制备方法,其特征在于:所述配料罐的蒸汽压控制为0.2-0.4MPa。
9.根据权利要求8所述的改善宠物肝功能的处方膏的制备方法,其特征在于:所述配料罐的蒸汽压优选为0.3MPa。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810878576.6A CN109170305A (zh) | 2018-08-03 | 2018-08-03 | 改善宠物肝功能的处方膏及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810878576.6A CN109170305A (zh) | 2018-08-03 | 2018-08-03 | 改善宠物肝功能的处方膏及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN109170305A true CN109170305A (zh) | 2019-01-11 |
Family
ID=64920088
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810878576.6A Pending CN109170305A (zh) | 2018-08-03 | 2018-08-03 | 改善宠物肝功能的处方膏及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN109170305A (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113304173A (zh) * | 2021-05-11 | 2021-08-27 | 奥启(深圳)创投科技有限公司 | 一种改善肝功能障碍的干细胞制剂 |
CN114190488A (zh) * | 2021-12-17 | 2022-03-18 | 南京泛成生物科技有限公司 | 一种宠物护肝营养膏及制备方法 |
CN115192672A (zh) * | 2022-07-06 | 2022-10-18 | 南京喜宠生物医学科技有限公司 | 一种保护犬猫肝脏的复合益生菌制剂及制备方法 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1104039A (zh) * | 1993-12-22 | 1995-06-28 | 黄明和 | 饲料程际添加剂 |
CN104288181A (zh) * | 2014-10-27 | 2015-01-21 | 武汉中博绿亚生物科技有限公司 | 一种治疗宠物因驱虫导致不舒的膏剂及其制备方法 |
CN105533213A (zh) * | 2015-12-12 | 2016-05-04 | 江苏雅博动物保健品有限责任公司 | 一种维生素矿物质营养膏及其制备方法 |
CN107691838A (zh) * | 2017-09-20 | 2018-02-16 | 深圳市红瑞生物科技有限公司 | 宠物绝育缓释膏及其制备方法 |
CN107691854A (zh) * | 2017-10-17 | 2018-02-16 | 深圳市红瑞生物科技有限公司 | 宠物眼疾膏及其制备方法 |
-
2018
- 2018-08-03 CN CN201810878576.6A patent/CN109170305A/zh active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1104039A (zh) * | 1993-12-22 | 1995-06-28 | 黄明和 | 饲料程际添加剂 |
CN104288181A (zh) * | 2014-10-27 | 2015-01-21 | 武汉中博绿亚生物科技有限公司 | 一种治疗宠物因驱虫导致不舒的膏剂及其制备方法 |
CN105533213A (zh) * | 2015-12-12 | 2016-05-04 | 江苏雅博动物保健品有限责任公司 | 一种维生素矿物质营养膏及其制备方法 |
CN107691838A (zh) * | 2017-09-20 | 2018-02-16 | 深圳市红瑞生物科技有限公司 | 宠物绝育缓释膏及其制备方法 |
CN107691854A (zh) * | 2017-10-17 | 2018-02-16 | 深圳市红瑞生物科技有限公司 | 宠物眼疾膏及其制备方法 |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113304173A (zh) * | 2021-05-11 | 2021-08-27 | 奥启(深圳)创投科技有限公司 | 一种改善肝功能障碍的干细胞制剂 |
CN114190488A (zh) * | 2021-12-17 | 2022-03-18 | 南京泛成生物科技有限公司 | 一种宠物护肝营养膏及制备方法 |
CN115192672A (zh) * | 2022-07-06 | 2022-10-18 | 南京喜宠生物医学科技有限公司 | 一种保护犬猫肝脏的复合益生菌制剂及制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109170305A (zh) | 改善宠物肝功能的处方膏及其制备方法 | |
Jing et al. | Evaluation of hypoglycemic activity of the polysaccharides extracted from Lycium barbarum | |
CN1457808A (zh) | 一种铁皮石斛复方制剂及制备和应用 | |
CN108524814A (zh) | 一种用于降低血糖的中药组合物及其制备方法 | |
WO2005115427A1 (en) | Herbal medicine composition for suppression of obesity and preparation method thereof | |
CN103734696B (zh) | 一种提高免疫力、保护脏器的软胶囊及其制备方法 | |
CN103007208A (zh) | 一种防治肉种鸡脂肪肝出血综合征的中药组方 | |
CN101574476B (zh) | 用于辅助性降脂保肝的药材组合物 | |
CN102356876B (zh) | 一种防治女性早衰的保健食品及其制备方法 | |
CN1243743A (zh) | 一种治疗慢性肝病的药物及其制备方法 | |
CN1478508A (zh) | 一种治疗脂肪肝的中药组合物及其制备方法 | |
CN108617779B (zh) | 一种对化学性肝损伤有辅助保护作用的驼奶组合物 | |
CN103393097A (zh) | 具有醒酒护肝作用的保健食品 | |
CN113499366B (zh) | 一种具有同时降低血糖血脂功能的组合物及其制备方法 | |
JP2003171303A (ja) | 特定植物含有組成物と該組成物を有効成分とする医薬品と保健用食品 | |
Jing et al. | Antihyperglycemic activity of polysaccharide from Lycium barbarum | |
CN103157061A (zh) | 一种用于乳腺增生的纯中药药物组合及其制备方法 | |
CN109316565B (zh) | 一种降血脂组合物及其制备方法和应用 | |
KR20100061212A (ko) | 측백엽, 백자인, 노간주나무 및/또는 참취의 추출 혼합물을유효성분으로 함유하는 비만 또는 지질관련 대사성질환의 예방 또는 치료용 약학적 조성물 | |
CN109043129A (zh) | 增强宠物心脏功能的处方膏及其制备方法 | |
CN1371746A (zh) | 一种具有调节血脂和治疗化学性肝损伤作用的中药组合物 | |
CN101269152A (zh) | 枸杞子和黑木耳在制备抗脂肪肝药物中的应用 | |
CN101167887A (zh) | 口服治疗糖尿病肾病的枸杞单方中药及其制备方法 | |
KR100573592B1 (ko) | 비만치료·억제용 백모근 추출물 | |
KR20190111726A (ko) | 천연 혼합 추출물을 포함하는 비만 예방 또는 치료용 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190111 |
|
RJ01 | Rejection of invention patent application after publication |